SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors
- PMID: 34510657
- PMCID: PMC8586659
- DOI: 10.1111/cas.15132
SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors
Abstract
Comprehensive genomic profiling enables the detection of genomic biomarkers in advanced solid tumors. However, efficient patient screening for the success of precision oncology remains challenging due to substantial barriers, such as genotyping costs and accessibility to matched therapies. To address these challenges, we launched GI-SCREEN, a nationwide gastrointestinal cancer genomic screening project within the SCRUM-Japan network in 2015 with the specific purpose of matching patients with a diverse portfolio of affiliated interventional targeted therapy trials. Subsequently, we initiated the molecular profiling projects GOZILA, MONSTAR-SCREEN-1, and MONSTAR-SCREEN-2, which incorporate tissue and plasma multiomics approaches to accurately identify patients with advanced solid tumors who would benefit from matched therapies. These projects have led to a significant increase in patient participation in targeted clinical trials and the approval of several therapeutics and companion diagnostics. Additionally, clinicogenomic analyses utilizing the SCRUM-Japan database have provided new insights into the molecular mechanisms of advanced solid tumors. In this review, we describe the path to the realization of cancer precision medicine for patients with advanced solid tumors based on the SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN platforms.
Keywords: circulating tumor DNA; multiomics; next-generation sequencing; precision oncology; real-world data.
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Conflict of interest statement
TF, WO, and KT have no conflict of interest to declare. YN reports research funding received from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Guardant Health, Inc, Genomedia, Inc, and Seagen, Inc. HT reports grants from Takeda, Daiichi Sankyo, Sysmex, and Taiho, as well as personal fees from Takeda, Eli Lilly and Company, Taiho, and Chugai. HB reports research funding received from AstraZeneca, Sysmex, and honoraria from Taiho Pharmaceutical and Eli Lilly Japan. TY reports Taiho Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Amgen KK, Parexel International Inc, MSD KK, Daiichi Sankyo Co., Ltd., and Sanofi KK. AO reports research funding received from Astellas, Astra‐Zeneca, Amgen, BMS, Boehringer‐Ingelheim, Chugai, Daiichi‐Sankyo, Dainippon‐Sumitomo, Elli‐Lilly, Eisai, Jansen pharma, Kyowa‐Kirin, MBL, Merck Serono, MSD, Novartis, Ono Pharma, Pfizer, Taiho, and Takeda. AO also reports an immediate family member employed by AZD.
Figures
![FIGURE 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586659/bin/CAS-112-4425-g001.gif)
![FIGURE 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8586659/bin/CAS-112-4425-g003.gif)
Similar articles
-
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020649 Clinical Trial.
-
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.JCO Precis Oncol. 2023 Mar;7:e2200653. doi: 10.1200/PO.22.00653. JCO Precis Oncol. 2023. PMID: 36996376 Free PMC article.
-
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.Int J Clin Oncol. 2024 May;29(5):495-511. doi: 10.1007/s10147-024-02493-4. Epub 2024 Mar 29. Int J Clin Oncol. 2024. PMID: 38551727 Free PMC article. Review.
-
Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies.Oncology (Williston Park). 2021 Jul 17;35(7):382-389. doi: 10.46883/ONC.2021.3507.0382. Oncology (Williston Park). 2021. PMID: 34286943
-
[Precision Medicine for Advanced Solid Malignancies Based on Circulating Tumor DNA Analysis].Gan To Kagaku Ryoho. 2020 Dec;47(12):1645-1652. Gan To Kagaku Ryoho. 2020. PMID: 33342975 Review. Japanese.
Cited by
-
Future direction of total neoadjuvant therapy for locally advanced rectal cancer.Nat Rev Gastroenterol Hepatol. 2024 Jun;21(6):444-455. doi: 10.1038/s41575-024-00900-9. Epub 2024 Mar 14. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38485756 Review.
-
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.Cancer Sci. 2024 May;115(5):1622-1633. doi: 10.1111/cas.16109. Epub 2024 Mar 1. Cancer Sci. 2024. PMID: 38429886 Free PMC article.
-
Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.Br J Cancer. 2024 Apr;130(7):1157-1165. doi: 10.1038/s41416-023-02540-3. Epub 2024 Feb 7. Br J Cancer. 2024. PMID: 38326601 Free PMC article.
-
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).Br J Cancer. 2023 Oct;129(6):1032-1039. doi: 10.1038/s41416-023-02378-9. Epub 2023 Aug 2. Br J Cancer. 2023. PMID: 37532830
-
The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan.Cancer Biol Med. 2023 May 3;21(1):29-44. doi: 10.20892/j.issn.2095-3941.2023.0036. Cancer Biol Med. 2023. PMID: 37133223 Free PMC article. Review.
References
-
- National Comprehensive Cancer Network Guidelines https://wwwnccnorg/guidelines/category_1. 2021. Accessed on July 21, 2021.
-
- Yoshino T, Arnold D, Taniguchi H, et al. Pan‐Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO‐ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29:44‐70. - PubMed
-
- Bando H. The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr Probl Cancer. 2017;41:166‐175. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources